


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


IFW

 <b>TRANSMITTAL FORM</b> <small>(to be used for correspondence after initial filing)</small>		Application Number <b>09/918,026</b> Filing Date <b>07-30-2001</b> First Named Inventor <b>Rosanne M. Crooke</b> Art Unit Examiner Name Attorney Docket Number <b>ISPH-0588</b>
<small>Number of Pages in This Submission</small> <b>34</b>		

**ENCLOSURES (Check all that apply)**

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached  <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)  <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers  <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input checked="" type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address  <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund  <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC  <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences  <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)  <input type="checkbox"/> Proprietary Information  <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):  <i>table</i>
<small>Remarks</small> Statement under 3.73(b)  <i>table</i>		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name	Isis Pharmaceuticals, Inc.		
Signature			
Printed name	Donna T. Ward, Ph.D.		
Date	9-30-05	Reg. No.	48,271


**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Pamela Grooms	Date	9-30-2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**REVOCATION OF POWER OF  
ATTORNEY WITH  
NEW POWER OF ATTORNEY  
AND  
CHANGE OF CORRESPONDENCE ADDRESS**

Application Number	See Attached Table
Filing Date	See Attached Table
First Named Inventor	See Attached Table
Art Unit	
Examiner Name	
Attorney Docket Number	See Attached Table

**I hereby revoke all previous powers of attorney given in the above-identified application.** A Power of Attorney is submitted herewith.**OR** I hereby appoint the practitioners associated with the Customer Number: 55,389 Please change the correspondence address for the above-identified application to: The address associated with  
Customer Number: 55,389**OR** Firm or  
Individual Name

Address

City

State

Zip

Country

Telephone

Fax

I am the:

 Applicant/Inventor.  
 Assignee of record of the entire interest. See 37 CFR 3.71.  
*Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)***SIGNATURE of Applicant or Assignee of Record**Signature Name Grantland E. Bryce, Esq.Date 09/29/2005Telephone 760 931-9200

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below\*.

 \*Total of 1 forms are submitted.

This collection of information is required by 37 CFR 1.36. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

**STATEMENT UNDER 37 CFR 3.73(b)**Applicant/Patent Owner: Isis Pharmaceuticals, Inc.Application No./Patent No.: See Attached Table Filed/Issue Date: See Attached TableEntitled: See Attached Table

Isis Pharmaceuticals, Inc., a Corporation  
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

- the assignee of the entire right, title, and interest; or
- an assignee of less than the entire right, title and interest.  
The extent (by percentage) of its ownership interest is \_\_\_\_\_ %

in the patent application/patent identified above by virtue of either:

A  An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel See Attached Table, Frame See Attached Table, or for which a copy thereof is attached.

**OR**

B  A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:


1. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.
2. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.
3. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

Additional documents in the chain of title are listed on a supplemental sheet.

Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

09/29/2005

Signature

Date

Grantland E. Bryce, Esq.760 931-9200

Printed or Typed Name

Telephone Number

Vice President and General Counsel

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*



Table A

Serial Number	Filing Date	Title	Reel	Frame	Inventor	Docket Number	New Customer Number
11/042,899	01/24/2005	MODULATION OF EIF4E-BP2 EXPRESSION	16057	850	Bhanot, Sanjay	RTS-0731US	34,138
11/117,013	04/27/2005	ANTISENSE MODULATION OF P70 S6 KINASE EXPRESSION	16573	847	Bennett, C. Frank	BNDL-0023US.P1	34,138
60/609,711	09/13/2004	COMPOSITIONS AND THEIR USES DIRECTED TO GEMIN GENES	18522	611	Dobie, Kenneth W.	RTS-0491US.L	34,138
60/624,292	11/01/2004	COMPOSITIONS AND THEIR USES DIRECTED TO SERINE/THREONINE KINASES	15639	443	Baker, Brenda F.	DPTK-0024US.L	34,138
60/624,387	11/01/2004	COMPOSITIONS AND THEIR USES DIRECTED TO TGFB1	15994	110	Dobie, Kenneth W.	DPTK-0015US.L	34,138
60/659,535	03/07/2005	COMPOSITIONS AND THEIR USES DIRECTED TO ALK	16219	360	Karras, James G.	BIOLO053US.L	34,138
60/664,399	03/22/2005	COMPOSITIONS AND THEIR USES DIRECTED TO ANGIOPOIETIN-LIKE 3	16271	814	Dobie, Kenneth W.	BIOLO055US.L	34,138
60/664,682	03/22/2005	COMPOSITIONS AND THEIR USES DIRECTED TO PLTP	16271	806	Dobie, Kenneth W.	BIOLO056US.L	34,138
60/672,462	04/18/2005	COMPOSITIONS AND THEIR USES DIRECTED TO CDC27	16248	885	Bennett, C. Frank	BIOLO059US.L	34,138
09/918,026	07/30/2001	ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EXPRESSION	12619	788	Crooke, Rossanne M.	ISPH-0588	55,389
09/920,394	08/01/2001	ANTISENSE MODULATION OF ACYL COENZYME A CHOLESTEROL ACYLTRANSFERASE-1 EXPRESSION	13035	175	Crooke, Rossanne M.	ISPH-0589	55,389
09/923,515	08/07/2001	ANTISENSE MODULATION OF APOLIPOPROTEIN (a) EXPRESSION	12437	796	Crooke, Rossanne M.	ISPH-0595	55,389
09/980,953	04/19/2002	ANTISENSE MODULATION OF B7 PROTEIN EXPRESSION (as amended)	13345	56	Bennett, C. Frank	ISPH-0621	55,389
10/485,113	05/21/2004	ANTISENSE MODULATION OF APOLIPOPROTEIN (a) EXPRESSION	15531	219	Crooke, Rossanne M.	ISPH-0690USA	55,389
10/633,843	08/04/2003	ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION	11953	651	Bennett, C. Frank	RTS-0242US.C1	55,389